Syneos Health ((SYNH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The COGNIKET-MCI Trial is a pivotal clinical study aimed at evaluating the effects of a nutritional intervention involving Ketogenic Medium-chain Triglycerides (kMCT) and B-vitamins on cognitive functioning in older adults with mild cognitive impairment. This multi-center, multi-country trial is significant as it explores potential dietary solutions to improve cognitive health in an aging population.
Intervention/Treatment: The study tests a dietary supplement called BrainXpert, which contains 15 g of kMCT and B-vitamins (B3, B6, B9/folic acid, and B12) in a powder format. The purpose is to assess its impact on cognitive function compared to a placebo made of high-oleic acid sunflower oil.
Study Design: This is a randomized, double-blind, placebo-controlled trial with a parallel intervention model. The study employs triple masking, meaning the participant, care provider, and investigator are unaware of the group assignments. The primary purpose is to investigate the cognitive benefits of the nutritional supplement.
Study Timeline: The study began on May 24, 2024, with the latest update submitted on August 11, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status, indicating active research efforts.
Market Implications: This study update could positively influence Syneos Health’s stock performance and investor sentiment, given the growing interest in nutritional interventions for cognitive health. As the lead sponsor, Société des Produits Nestlé may also see increased attention in the nutritional supplement market, potentially impacting competitors focused on similar cognitive health solutions.
The COGNIKET-MCI trial is ongoing, with further details available on the ClinicalTrials portal.